1999PubMedRequires access

[A study of mitoxantrone with other chemical agents in treating 126 cases of adult acute myeloid leukemia].

Y Chen, Jianfei Fu, Xin Du, Jingying Qiu, D Wang, Da‐Wen Lu

Open publisher page 0 citations

Abstract

OBJECTIVE: To estimate the effect of mitoxantrone with other chemical agents in treating adult acute myeloid leukemia. METHODS: 126 inpatients diagnosed as acute myeloid leukemia between January 1993 to December 1997 were treated with mitoxantrone with other chemical agents. 85 had not been treated previously, (untreated) while 51 were relapsing or resistant to previous treatment. RESULTS: The complete response rate among untreated and the relapsing/resistant groups were 44.7% and 27.5%; while the partial response rate were 20.0%, 9.8% respectively. 4 patients were in the untreated group died early. The main side-effect of mitoxantrone is bone marrow depression which led to fever and bleeding with rates of 40.4%, 24.3%. The non-bone marrow side-effects were tolerable. Damage to the liver was a prominent occurrence 31.8%. CONCLUSION: mitoxantrone was effective as the first line anti-tumor drug with other chemical agents in treating adult acute myeloid leukemia, its side-effects were mild.

About this research paper

What this paper is about

OBJECTIVE: To estimate the effect of mitoxantrone with other chemical agents in treating adult acute myeloid leukemia. METHODS: 126 inpatients diagnosed as acute myeloid leukemia between January 1993 to December 1997 were treated with mitoxantrone with other chemical agents. 85 had not been treated previously, (untreated) while 51 were relapsing or resistant to previous treatment. RESULTS: The complete response rate among untreated and the relapsing/resistant groups were 44.7% and 27.5%; while the partial response rate were 20.0%, 9.8% respectively. 4 patients were in the untreated group died early. The main side-effect of mitoxantrone is bone marrow depression which led to fever and bleeding with rates of 40.4%, 24.3%. The non-bone marrow side-effects were tolerable. Damage to the liver was a prominent occurrence 31.8%. CONCLUSION: mitoxantrone was effective as the first line anti-tumor drug with other chemical agents in treating adult acute myeloid leukemia, its side-effects were mild.

Why it matters

A significance statement is not available in the OpenAlex record.

Key contribution

A contribution statement is not available in the OpenAlex record.

Method / approach

Method details are not available in the OpenAlex metadata.

Main findings

Findings are not separately available in the OpenAlex metadata.

Limitations

Limitations are not available in the OpenAlex metadata.

Applications

Application details are not available in the OpenAlex metadata.

Available abstract

OBJECTIVE: To estimate the effect of mitoxantrone with other chemical agents in treating adult acute myeloid leukemia. METHODS: 126 inpatients diagnosed as acute myeloid leukemia between January 1993 to December 1997 were treated with mitoxantrone with other chemical agents. 85 had not been treated previously, (untreated) while 51 were relapsing or resistant to previous treatment. RESULTS: The complete response rate among untreated and the relapsing/resistant groups were 44.7% and 27.5%; while the partial response rate were 20.0%, 9.8% respectively. 4 patients were in the untreated group died early. The main side-effect of mitoxantrone is bone marrow depression which led to fever and bleeding with rates of 40.4%, 24.3%. The non-bone marrow side-effects were tolerable. Damage to the liver was a prominent occurrence 31.8%. CONCLUSION: mitoxantrone was effective as the first line anti-tumor drug with other chemical agents in treating adult acute myeloid leukemia, its side-effects were mild.

Key concepts: Mitoxantrone, Medicine, Myeloid leukemia, Leukemia, Internal medicine, Bone marrow, Acute leukemia, Myeloid

Related papers

Back to paper searchBrowse research topicsOriginal source
[A study of mitoxantrone with other chemical agents in treating 126 cases of adult acute myeloid leukemia]. — Research Paper | ScholarLens